Feature in Daily Mail3 Sep 2021 08:34
BIOTECHNOLOGY firm Tiziana Life Sciences notched up healthy gains, rising 14.2pc, or 8.7p, to 70.2p after unveiling an exclusive licence agreement for its antibody product, known as Foralumab, with US firm Precision Biosciences.
Foralumab is designed to enhance CAR-T therapy, a new type of treatment for blood-borne cancers. Precision will aim to use foralumab to increase the tolerance of CAR-T in patients and potentially increase its long-term viability as a cancer treatment.
In return for granting the licence, Tiziana will receive upfront and milestone payments as well as royalties